Libourne, France — February 9, 2026: Ceva Animal Health, the world’s fifth-largest animal health company, has announced strategic leadership restructuring across the Asia-Pacific and China regions, including the relocation of its regional headquarters to Shanghai. The organizational transformation is designed to accelerate regional growth, strengthen operational excellence, and expand veterinary health innovation across high-demand livestock and companion animal markets.
Science Significance
While primarily organizational, the restructuring carries important implications for veterinary pharmaceutical innovation, vaccine development, and preventive animal health science. Ceva’s regional expansion strengthens its capacity to deliver vaccines, biologics, and pharmaceutical solutions across diverse species, including livestock and companion animals. Enhanced leadership oversight in Asia-Pacific—one of the fastest-growing animal health markets—supports accelerated deployment of preventive medicine platforms, welfare therapeutics, and disease surveillance technologies. By aligning commercial leadership closer to emerging disease ecosystems, the company enhances translational pathways from R&D to field implementation.
Regulatory Significance
Regional headquarters relocation to Shanghai positions Ceva closer to regulatory authorities, veterinary health ministries, and market authorization bodies governing animal biologics and pharmaceuticals. Strengthened regional governance supports compliance with veterinary GMP manufacturing oversight, biologics batch release frameworks, and pharmacovigilance reporting systems. Organizational alignment across APAC and China also facilitates streamlined regulatory submissions, localized clinical validation, and adherence to region-specific product registration pathways—critical in markets with evolving veterinary regulatory landscapes.
Business Significance
Advertisement
The leadership realignment reflects Ceva’s long-term commercial strategy to deepen penetration in high-growth markets. Appointment of Arnaud Leboulanger as Senior Vice President of the APAC & China region brings seasoned international operational expertise, supporting transformation and market expansion initiatives. Concurrently, Anh-Mai Vu’s appointment as Head of Pet Products strengthens companion animal portfolio commercialization and digital market development. These leadership appointments reinforce Ceva’s strategic focus on innovation, customer engagement, and scalable regional growth across veterinary therapeutics and preventive health solutions.
Patients’ Significance
In veterinary health, “patients” span both livestock populations and companion animals. Strengthened regional leadership enhances access to vaccines, anti-infectives, welfare therapeutics, and preventive care solutions that directly impact animal survival, productivity, and well-being. Expanded operational reach supports disease control in food-producing animals while improving treatment availability for pets, contributing to better herd health outcomes, food security stability, and companion animal quality of life.
Policy Significance
The restructuring aligns with broader One Health policy frameworks, which recognize the interconnectedness of animal health, human health, and environmental systems. Strengthening veterinary infrastructure across Asia-Pacific supports zoonotic disease prevention, antimicrobial stewardship, and sustainable livestock production. By positioning leadership closer to regional public health ecosystems, Ceva enhances collaboration with governmental and agricultural agencies addressing biosecurity, vaccination coverage, and animal welfare governance.
Ceva Animal Health’s APAC and China leadership transformation marks a strategic step toward reinforcing its global veterinary health footprint. By aligning executive leadership, regional headquarters, and operational strategy, the company is positioned to accelerate innovation delivery, regulatory alignment, and market expansion across one of the world’s most dynamic animal health regions. The move underscores Ceva’s commitment to advancing preventive veterinary medicine, pharmaceutical solutions, and sustainable animal care ecosystems worldwide.
Source: Ceva Animal Health press release
